3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Neoplastic Cells, Circulating
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematopoietic and Lymphoid System Neoplasm
1
Head and Neck Neoplasms
1
Glioma
1
Disease
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colonic Neoplasms
1
Carcinoma, Lobular
1
Interventions
Pemetrexed
14
Carboplatin
13
osimertinib
10
Drug Therapy
9
aflutinib
8
Gefitinib
7
Radiotherapy
6
Docetaxel
6
Cisplatin
6
anlotinib
5
Radiosurgery
5
Paclitaxel
5
pembrolizumab
4
Vinorelbine
4
Gemcitabine
4
tislelizumab
3
icotinib
3
apatinib
3
HM781-36B
3
Erlotinib Hydrochloride
3
toripalimab
2
spartalizumab
2
rezivertinib
2
camrelizumab
2
Tyrosine Kinase Inhibitors
2
Thalidomide
2
Surgical Procedures, Operative
2
S 1 (combination)
2
Platinum
2
Immune Checkpoint Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
NSCLC
×
Liquid Biopsy
×
Clear all
NCT02890849
2024-02-23
RadImm01
Xinqiao Hospital of Chongqing
Phase NA
Completed
60 enrolled